Harmony BiosciencesvsMerck & Company

HRMY and MRK stock compared: price, dividend, valuation and results, from SEC filings.

HRMY

Harmony Biosciences Holdings, Inc.

$32.98

Value $1.9B

+0.30%
HRMY's page

MRK

Merck & Company, Inc.

$132.81

Value $328B

-3.61%
MRK's page

Harmony Biosciences (HRMY) has a market value of $1.9B and Merck & Company (MRK) $328B. Over the last year, with dividends, HRMY moved -2.6% and MRK +52.7%. The P/E is 10.7 for HRMY and 133.9 for MRK. Dividend yield: HRMY none, MRK 2.56%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    HRMY$1.9B

    MRK$328B

    MRK is 172 times HRMY

  • Revenue, 12 months

    HRMY$989M

    MRK$67.4B

    MRK is 68 times HRMY

  • Net income, 12 months

    HRMY$179M

    MRK$2.5B

    MRK is 14 times HRMY

  • Operating margin

    HRMY22.2%

    MRK–

  • ROIC

    HRMY15.3%

    MRK3.9%

    11.4 points apart

  • P/E

    HRMY10.7

    MRK133.9

    MRK is 13 times HRMY

  • Dividend yield

    HRMY0.0%

    MRK2.6%

    2.6 points apart

  • 5-year return

    HRMY-17.5%

    MRK+94.3%

    111.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

HRMY-17.5%

MRK+94.3%

5010015020020222023202420252026
Returns by period
PeriodHRMYWith dividendsMRKWith dividends
1 year since November 17, 2025-2.6%Price -2.6%+52.7%Price +48.4%
3 years since November 17, 2023+22.8%+7.1% a yearPrice +22.8%+48.4%+14.1% a yearPrice +35.4%
5 years since November 17, 2021-17.5%-3.8% a yearPrice -17.5%+94.3%+14.2% a yearPrice +66.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

HRMYHarmony BiosciencesMRKMerck & Company

Valuation

HRMYMRK
Valuation
Price$32.98$132.81
Market value$1.9B$328B
Enterprise value (EV)$1.3B$372B
P/E10.7133.9
P/E, 5-year median15.214.8
P/B1.87.3
EV/EBIT5.978.2
Free cash flow yield16.9%4.5%

Results and growth

HRMYMRK
Results and growth
Revenue, 12 months$989M$67.4B
Net income, 12 months$179M$2.5B
Free cash flow, 12 months$323M$14.7B
Earnings per share, 12 months$3.03$0.98
Revenue growth, year on year21.5%1.3%
Revenue growth a year, past+40.3%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

HRMYMRK
Margins and returns on capital
Gross margin74.0%71.8%
Operating margin22.2%–
Net margin18.1%3.6%
ROIC15.3%3.9%
ROE19.1%5.2%

Balance sheet

HRMYMRK
Balance sheet
Cash$771M$9.7B
Total debt$155M$53.8B
Net debt / EBITDA–5.7
Interest cover17.0×2.4×

Dividends and buybacks

HRMYMRK
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.6%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: HRMY or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Harmony Biosciences or Merck & Company?

By market value, Merck & Company ($328B) is about 172.1 times Harmony Biosciences ($1.9B), at today's prices.

How did HRMY and MRK stock do over the last 5 years?

Since November 17, 2021, HRMY's price moved -17.5% and MRK's +66.8%. With dividends: HRMY -17.5% (-3.8% a year), MRK +94.3% (+14.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, HRMY or MRK?

The dividend yield at today's price is none for Harmony Biosciences and 2.56% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of HRMY and MRK?

At today's price, the P/E is 10.7 for HRMY and 133.9 for MRK. The median of the last five years was 15.2 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Harmony Biosciences or Merck & Company?

Over the last twelve months, the net margin was 18.1% for Harmony Biosciences and 3.6% for Merck & Company, and the operating margin 22.2% and –. Revenue was $989M and $67.4B.

Which is the better investment, Harmony Biosciences or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.